about
Clinical use of pasireotide for Cushing's disease in adultsPrevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasiaAge and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample.Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature.AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up.A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.Sleep apnea syndrome in endocrine clinics.Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.Body Composition is Different After Surgical or Pharmacological Remission of Cushing's Syndrome: A Prospective DXA Study.The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp- somatotropinomas.Cushing's Syndrome: Screening and Diagnosis.Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing's disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentPredicting late recurrence in surgically treated patients with Cushing's disease.Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome.Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome.First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS.A venous thromboembolism risk assessment model for patients with Cushing's syndrome.Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS.The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.Early recognition of aggressive pituitary adenomas: a single-centre experience.Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus.Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study.Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma.Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study.Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM).Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency.Diagnosis and complications of Cushing's disease: gender-related differences.Radiotherapy in acromegaly: Long-term brain parenchymal and vascular magnetic resonance changes.Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?Acromegaly Is More Severe in Patients With AHR or AIP Gene Variants Living in Highly Polluted Areas.Diabetes Mellitus Secondary to Cushing's Disease.Paradoxical GH increase during OGTT is associated to first-generation somatostatin analogs responsiveness in acromegalySecondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal TumorThe Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome.Intracranial internal carotid artery changes in acromegaly: a quantitative magnetic resonance angiography studyCombination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?Salivary cortisol and cortisone by LC-MS/MS: validation, reference intervals and diagnostic accuracy in Cushing's syndrome
P50
Q26858933-9F272540-B823-4A98-9DD5-2970C9B34AA9Q28284546-11303913-4188-430E-90B4-454DFECC7BE4Q30981349-3177D125-07CD-4A96-886C-38B75F354FF4Q33419582-42EF66E7-F344-44C5-8FBF-407FCB703629Q33816554-73CD6154-9840-4AE3-AC05-2E057DF24EDBQ33895577-52690AEC-077B-442D-B926-2F9D3B6F7464Q36544784-F6636449-967D-4AC2-90C2-FBC5AB9EB52EQ38540035-20BFD7C7-D937-4FFA-ADE4-FB74EE2F3FEEQ38650974-AEC4FF39-5335-41FE-93D0-12E4E9FCD756Q38674405-963DA651-B903-4343-B6B4-F78C9130F009Q38717209-7AF01EE9-6605-480B-B49F-332551A337C3Q38830068-E6FF1620-EBF5-4B3F-8A02-01E60EBA2060Q38985205-4E005904-D287-422E-9E7A-759FF960EFD2Q39493301-48C9B743-6ED9-4B58-8924-A2FB1ED7710DQ39728429-80767AD7-2691-4D08-9A33-BA0556ED0D3CQ39761422-7C57712A-6DBF-497A-877B-20C8F981C56AQ40169381-C92EA764-9368-4076-BC85-B4FEEBF3708FQ40313813-361FA7E2-5764-49E3-94F0-F3023F6D22DCQ40795123-3D752BC6-5D56-45FB-B1E0-FF6EBA2C10C3Q41482557-6B3105BB-4004-47E2-B801-67AA9C934C20Q41698329-B90BF868-EE33-4298-ADC0-BB6B289FA736Q46649628-FAE67AE4-F24B-488A-92EA-9EBF1F588346Q47573398-938360F4-0EB4-4D6E-B6AD-F590C9D93A24Q47729136-6E4C3C3B-5364-4AC4-BEF3-098BA665F948Q48251457-C16AE13E-9A39-48CD-B411-25C1EA05B512Q48278106-92F0C76B-53B4-4AEC-BA18-DD517997793BQ48703996-D7029681-6C9D-40DF-9C09-C65E1B6578AEQ49893436-29E772B4-2A65-44BE-8D00-C7E7E7B044B8Q50906754-3387B238-DA83-465C-8D51-2524911298C9Q51221036-E929A4A4-5105-42AC-916E-8D94C7858DF1Q51744308-C7C291CF-1946-4D0F-8FAD-FBB5C32D846AQ53439990-22F6D51D-8293-431D-B479-BBF07DAC3786Q53793757-885A560E-4DEA-4062-BEDC-68937C8B17D0Q55425212-24C0D215-52FE-4541-855E-82ED59D61F81Q57037753-3A75E757-47AD-4B73-AD2A-F73EDD084849Q58556463-D8D266A4-B062-4DFF-91AC-C347E94511D3Q64986758-322D985C-948F-4DB4-BB28-91F99C71EA5FQ86040329-D12040D6-4744-4C6F-9DA3-6B808B281514Q86299876-AFE7F36A-01AE-41F8-B5EE-ADF13CDE3D00Q86423862-BC77182B-180E-47D6-8AB3-15275FE6D760
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Filippo Ceccato
@ast
Filippo Ceccato
@en
Filippo Ceccato
@es
Filippo Ceccato
@nl
Filippo Ceccato
@sl
type
label
Filippo Ceccato
@ast
Filippo Ceccato
@en
Filippo Ceccato
@es
Filippo Ceccato
@nl
Filippo Ceccato
@sl
prefLabel
Filippo Ceccato
@ast
Filippo Ceccato
@en
Filippo Ceccato
@es
Filippo Ceccato
@nl
Filippo Ceccato
@sl
P106
P1153
26031227200
P31
P496
0000-0003-1456-8716